Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Key Points

• Inovio beat earnings expectations: The company reported a quarterly loss of $0.07 per share, $0.15 better than the consensus estimate of a $0.22 loss.
• INO-3107 remains on track for FDA review: The treatment’s October 30, 2026 PDUFA date is intact, and Inovio is advancing launch preparations, though accelerated approval and final timing remain uncertain.
• Funding remains a concern: Inovio ended the quarter with $36.7 million in cash and expects about $18 million in operational cash burn during the third quarter; a July equity offering is expected to fund operations into late Q1 2027, excluding additional capital raises.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15, FiscalAI reports.

Here are the key takeaways from Inovio Pharmaceuticals' conference call:

• Positive Sentiment: INO-3107’s FDA review remains on track for the October 30, 2026 PDUFA date; late-cycle review and pre-licensure inspections are complete, with only one reported inspection observation that the company believes it has addressed.
• Positive Sentiment: Inovio is advancing launch preparations for INO-3107, including label negotiations expected to begin in September, medical science liaison activities, and a commercialization agreement with Syneos Health. If approved, the company expects seven years of orphan-drug market exclusivity.
• Negative Sentiment: The FDA has not yet indicated whether INO-3107 qualifies for accelerated approval, and feedback on the confirmatory-trial design remains outstanding. The company continues to characterize approval and launch timing as potential outcomes rather than assured results.
• Negative Sentiment: Inovio ended the quarter with $36.7 million in cash, cash equivalents, and short-term investments, and expects approximately $18 million of operational net cash burn in Q3. July’s $18.3 million equity offering extends funding into late Q1 2027 and through a potential launch, but the company noted that this projection excludes future capital raises.
• Positive Sentiment: Partner ApolloBio reported positive pivotal Phase III results for VGX-3100 in cervical dysplasia, meeting its primary efficacy endpoint and supporting plans for a potential regulatory filing in China. Inovio also reported encouraging preclinical progress for its DPROT platform in hemophilia A and other rare diseases.

Inovio Pharmaceuticals Price Performance

Inovio Pharmaceuticals stock traded up $0.00 during mid-day trading on Wednesday, hitting $0.77. 3,060,340 shares of the company were exchanged, compared to its average volume of 2,293,542. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.98. The company has a market capitalization of $63.35 million, a P/E ratio of -0.53 and a beta of 1.52. The business's 50 day simple moving average is $1.04 and its two-hundred day simple moving average is $1.31.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on INO shares. Wall Street Zen cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, June 21st. HC Wainwright lowered their target price on Inovio Pharmaceuticals from $3.00 to $2.50 and set a "neutral" rating on the stock in a report on Monday, June 1st. Weiss Ratings upgraded Inovio Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 29th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $4.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.25.

Institutional Trading of Inovio Pharmaceuticals

A number of large investors have recently made changes to their positions in INO. Millennium Management LLC raised its position in shares of Inovio Pharmaceuticals by 468.7% in the third quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company's stock valued at $4,616,000 after buying an additional 1,625,653 shares during the last quarter. Vanguard Group Inc. boosted its position in Inovio Pharmaceuticals by 35.0% during the third quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company's stock worth $6,348,000 after acquiring an additional 703,727 shares during the last quarter. 683 Capital Management LLC acquired a new stake in Inovio Pharmaceuticals during the fourth quarter worth approximately $433,000. OMERS ADMINISTRATION Corp purchased a new stake in Inovio Pharmaceuticals in the 4th quarter worth approximately $388,000. Finally, Geode Capital Management LLC grew its stake in Inovio Pharmaceuticals by 40.7% in the 4th quarter. Geode Capital Management LLC now owns 769,356 shares of the biopharmaceutical company's stock worth $1,340,000 after acquiring an additional 222,609 shares during the period. Institutional investors and hedge funds own 26.79% of the company's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source